FINANCINGS

Aimmune Therapeutics Inc. received a $145 million equity investment from Nestlé Health Science.

Axsome Therapeutics Inc. entered a $20 million term loan agreement with Silicon Valley Bank.

Curevac AG added $29.5 million in new funds from German investors.

Omeros Corp. used about $76 million from a new $80 million term loan to repay its obligations under a previous credit facility with less favorable terms.

Pixarbio Corp. completed the closing of the sale of common shares and warrants in a private placement transaction resulting in expected proceeds of approximately $23.4 million plus a $10 million line of credit.

Progenics Pharmaceuticals Inc.'s wholly owned subsidiary MNTX Royalties Sub LLC has entered a $50 million term loan agreement with a fund managed by Healthcare Royalty Partners (HCR) secured by, and to be repaid from, royalties from future sales of Relistor, a treatment for opioid-induced constipation.

Therapix BioSciences filed its form F-1 with the SEC in order to raise up to $12 million in an IPO.

DEALS

Adalta Ltd. and XL-protein GmbH said they will collaborate on the development and commercialization of a long-acting form of AD-114, a first-in-class drug candidate for fibrosis therapy.

Artes Biotechnology GmbH and Biosun Pharmed said they will jointly develop and manufacture a human papillomavirus vaccine in Iran.

Axiogenesis AG and Metrion Biosciences Ltd. entered a collaboration to work on iPSC-derived cell based assays.

Cancer Research UK and its commercial arm, Cancer Research Technology (CRT), signed an agreement with Tyg Oncology Ltd. to take its new antigen-specific, active checkpoint control cancer vaccine, TYG100, into clinical trials in cancer patients with advanced solid tumors.

Cell Medica Ltd. said it expanded its partnership with Baylor College of Medicine to develop an off-the-shelf allogeneic cell therapy, taking advantage of invariant natural killer T (NKT) cells.

Dnatrix Inc. entered an exclusive license agreement with the University of Florida, Gainesville, to develop an oncolytic virus platform.

Fortress Biotech Inc. has formed a subsidiary, Cellvation Inc., to develop treatments for traumatic brain injury (TBI), and has inked an agreement with the University of Texas Health Science Center at Houston for exclusive worldwide rights to three programs for TBI.

IBM Watson Health and the Broad Institute of MIT and Harvard University announced a research initiative aimed at discovering the basis of cancer drug resistance.

Orexigen Therapeutics Inc. said a wholly owned subsidiary of Valeant Pharmaceuticals International Inc. will commercialize Contrave (naltrexone HCl/bupropion HCl extended release) in Australia and New Zealand.

. . . AND MORE

Abbvie Inc. received FDA orphan designation for veliparib, its oral PARP inhibitor, in combination with chemotherapies or radiation for the treatment of advanced squamous non-small-cell lung cancer.

Emmaus Life Sciences Inc. gained FDA acceptance of its new drug application (NDA) for pharmaceutical-grade L-glutamine as a treatment for sickle cell disease.

Gilead Sciences Inc.'s Vemlidy – better known as tenofovir alafenamide, or TAF – won FDA approval for treating adults with chronic hepatitis B virus (HBV) infection with compensated liver disease.

The FDA's Antimicrobial Drugs Advisory Committee (AMDAC) panel endorsed the efficacy of Cempra Inc.'s solithromycin to treat community-acquired bacterial pneumonia (CABP) with a 13-0 vote.

The Medicines Co. said it discontinued the clinical development program for MDCO-216, its investigational cholesterol efflux promoter.

No Comments